Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807879 | 0.89 | XDH (0.49) | XDHMAOBFFAR1FFAR4MRGPRX4 | |
| SCHEMBL23874972 | 0.87 | XDH (0.55) | XDHMAOBFFAR1FFAR4MRGPRX4 | |
| SCHEMBL24066320 | 0.84 | XDH (0.50) | XDHMAOBMRGPRX4HPGDAR | |
| SCHEMBL6817638 | 0.84 | SGMS2 (0.47) | XDHMRGPRX4LMNAHPGD | |
| SCHEMBL21884785 | 0.83 | MAOB (0.47) | XDHMAOBMRGPRX4LMNAHPGD | |
| SCHEMBL9724299 | 0.81 | HPGD (0.56) | FFAR4LMNAHPGD | |
| SCHEMBL20944114 | 0.80 | ALDH1A1 (0.49) | HPGD | |
| SCHEMBL9706364 | 0.79 | MAOB (0.58) | XDHMAOBFFAR1FFAR4MRGPRX4 | |
| SCHEMBL8143434 | 0.78 | HPGD (0.54) | XDHFFAR1FFAR4MRGPRX4LMNA | |
| SCHEMBL1495210 | 0.77 | MRGPRX4 (0.49) | FFAR4MRGPRX4LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | XDH 4012/4885MAOB 4461/4885FFAR1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.